Is Xtant Medical Stock a Good Investment?
Xtant Medical Investment Advice | XTNT |
- Examine Xtant Medical's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Xtant Medical's leadership team and their track record. Good management can help Xtant Medical navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Xtant Medical's business and its evolving consumer preferences.
- Compare Xtant Medical's performance and market position to its competitors. Analyze how Xtant Medical is positioned in terms of product offerings, innovation, and market share.
- Check if Xtant Medical pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Xtant Medical's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Xtant Medical Holdings stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Xtant Medical Holdings is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Xtant Medical Stock
Researching Xtant Medical's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 65.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 1.22. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Xtant Medical Holdings recorded a loss per share of 0.13. The entity last dividend was issued on the 14th of February 2018. The firm had 1:12 split on the 14th of February 2018.
To determine if Xtant Medical is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Xtant Medical's research are outlined below:
| Xtant Medical generated a negative expected return over the last 90 days | |
| Xtant Medical has some characteristics of a very speculative penny stock | |
| Xtant Medical has high historical volatility and very poor performance | |
| Xtant Medical has high likelihood to experience some financial distress in the next 2 years | |
| Xtant Medical Holdings currently holds about 16.5 M in cash with (9.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19. | |
| Xtant Medical has a poor financial position based on the latest SEC disclosures | |
| Roughly 65.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: lker Biskvi Sanayi Leads This Trio Of Stocks That May Be Underestimated By The Market |
Xtant Medical Quarterly Gross Profit |
|
Xtant Medical uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Xtant Medical Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Xtant Medical's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact Xtant Medical's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Xtant Medical's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-08 | 2024-06-30 | -0.02 | -0.03 | -0.01 | 50 | ||
2024-04-01 | 2024-03-31 | -0.02 | -0.03 | -0.01 | 50 | ||
2024-02-13 | 2023-12-31 | -0.02 | -0.03 | -0.01 | 50 | ||
2023-05-04 | 2023-03-31 | -0.03 | -0.02 | 0.01 | 33 | ||
2024-11-07 | 2024-09-30 | -0.02 | -0.04 | -0.02 | 100 | ||
2018-11-14 | 2018-09-30 | -0.17 | -0.21 | -0.04 | 23 | ||
2020-08-03 | 2020-06-30 | -0.11 | -0.19 | -0.08 | 72 | ||
2023-11-09 | 2023-09-30 | -0.02 | 0.07 | 0.09 | 450 |
Xtant Medical's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 55.6 M.Market Cap |
|
Xtant Medical's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.01 | 0.01 | |
| Return On Capital Employed | (0.15) | (0.15) | |
| Return On Assets | 0.01 | 0.01 | |
| Return On Equity | 0.01 | 0.01 |
Determining Xtant Medical's profitability involves analyzing its financial statements and using various financial metrics to determine if Xtant Medical is a good buy. For example, gross profit margin measures Xtant Medical's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Xtant Medical's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Xtant Medical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Xtant Medical Holdings. Check Xtant Medical's Beneish M Score to see the likelihood of Xtant Medical's management manipulating its earnings.
Evaluate Xtant Medical's management efficiency
Xtant Medical Holdings has return on total asset (ROA) of (0.1058) % which means that it has lost $0.1058 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0877) %, meaning that it created substantial loss on money invested by shareholders. Xtant Medical's management efficiency ratios could be used to measure how well Xtant Medical manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Xtant Medical's Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.01 in 2024, whereas Return On Capital Employed is likely to drop (0.15) in 2024. Change To Liabilities is likely to gain to about 1.9 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 16 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.43 | 0.45 | |
| Tangible Book Value Per Share | 0.29 | 0.30 | |
| Enterprise Value Over EBITDA | 30.03 | 31.54 | |
| Price Book Value Ratio | 2.62 | 2.49 | |
| Enterprise Value Multiple | 30.03 | 31.54 | |
| Price Fair Value | 2.62 | 2.49 | |
| Enterprise Value | 152.4 M | 107.5 M |
Leadership effectiveness at Xtant Medical Holdings is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 0.385 |
Basic technical analysis of Xtant Stock
As of the 30th of November, Xtant Medical maintains the Standard Deviation of 5.48, market risk adjusted performance of (1.46), and Mean Deviation of 3.25. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Xtant Medical Holdings, as well as the relationship between them.Xtant Medical's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Xtant Medical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Xtant Medical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Xtant Medical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sean Browne over a month ago Disposition of 105442 shares by Sean Browne of Xtant Medical at 0.59 subject to Rule 16b-3 | ||
Sean Browne over three months ago Disposition of 10606 shares by Sean Browne of Xtant Medical at 0.6 subject to Rule 16b-3 | ||
Sean Browne over six months ago Disposition of 80000 shares by Sean Browne of Xtant Medical at 0.6751 subject to Rule 16b-3 | ||
Michael Eggenberg over six months ago Acquisition by Michael Eggenberg of 46784775 shares of Xtant Medical at 1.07 subject to Rule 16b-3 | ||
Sean Browne over six months ago Acquisition by Sean Browne of 731632 shares of Xtant Medical subject to Rule 16b-3 | ||
Scott Neils over six months ago Acquisition by Scott Neils of 177551 shares of Xtant Medical subject to Rule 16b-3 | ||
Vizirgianakis Stavros G over a year ago Acquisition by Vizirgianakis Stavros G of 217770 shares of Xtant Medical subject to Rule 16b-3 |
Xtant Medical's Outstanding Corporate Bonds
Xtant Medical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Xtant Medical Holdings uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Xtant bonds can be classified according to their maturity, which is the date when Xtant Medical Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| XEROX HLDGS P Corp BondUS98421MAB28 | View | |
| XEROX HLDGS P Corp BondUS98421MAA45 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| US98420EAB11 Corp BondUS98420EAB11 | View |
Understand Xtant Medical's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Xtant Medical's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (1.46) | |||
| Mean Deviation | 3.25 | |||
| Coefficient Of Variation | (769.04) | |||
| Standard Deviation | 5.48 | |||
| Variance | 29.99 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.78) | |||
| Total Risk Alpha | (1.64) | |||
| Treynor Ratio | (1.47) | |||
| Maximum Drawdown | 35.77 | |||
| Value At Risk | (7.69) | |||
| Potential Upside | 5.45 | |||
| Skewness | (0.35) | |||
| Kurtosis | 10.71 |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (1.46) | |||
| Mean Deviation | 3.25 | |||
| Coefficient Of Variation | (769.04) | |||
| Standard Deviation | 5.48 | |||
| Variance | 29.99 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.78) | |||
| Total Risk Alpha | (1.64) | |||
| Treynor Ratio | (1.47) | |||
| Maximum Drawdown | 35.77 | |||
| Value At Risk | (7.69) | |||
| Potential Upside | 5.45 | |||
| Skewness | (0.35) | |||
| Kurtosis | 10.71 |
Consider Xtant Medical's intraday indicators
Xtant Medical intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Xtant Medical stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Xtant Medical time-series forecasting models is one of many Xtant Medical's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Xtant Medical's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Xtant Stock media impact
Far too much social signal, news, headlines, and media speculation about Xtant Medical that are available to investors today. That information is available publicly through Xtant media outlets and privately through word of mouth or via Xtant internal channels. However, regardless of the origin, that massive amount of Xtant data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Xtant Medical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Xtant Medical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Xtant Medical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Xtant Medical alpha.
Xtant Medical Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Xtant Medical can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Xtant Medical Corporate Management
| Scott Neils | Chief Officer | Profile | |
| Kevin ODare | VP US | Profile | |
| Catherine Lundy | Vice Resources | Profile | |
| Mark Schallenberger | Chief Officer | Profile |
Already Invested in Xtant Medical Holdings?
The danger of trading Xtant Medical Holdings is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Xtant Medical is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Xtant Medical. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Xtant Medical Holdings is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Xtant Stock Analysis
When running Xtant Medical's price analysis, check to measure Xtant Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xtant Medical is operating at the current time. Most of Xtant Medical's value examination focuses on studying past and present price action to predict the probability of Xtant Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xtant Medical's price. Additionally, you may evaluate how the addition of Xtant Medical to your portfolios can decrease your overall portfolio volatility.